Original ArticleThe International Classification of Retinoblastoma Predicts Chemoreduction Success
Section snippets
Patients and Methods
All new patients with retinoblastoma who were treated with initial CRD (Institutional Review Board approved CHP no. 582) on the Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, in conjunction with the Division of Oncology at The Children’s Hospital of Philadelphia, were identified. The eligibility criteria for treatment with CRD5 were children with retinoblastoma in whom either eye ordinarily would require enucleation or EBRT for cure of the disease based on published
Results
Between July, 1994, and June, 2004, 249 eyes of 163 patients were treated with the CRD protocol5, 10 and were included in this study. The percent success for each group and subgroup of the Reese–Ellsworth (Table 1) and ICRB (Table 2) classifications are listed in Table 3, Table 4, respectively (Figure 1, Figure 2). The mean patient follow-up was 6.2 years (median, 6.2; range, 1–10.6).
When assessing the eyes using the 5 major Reese–Ellsworth groups, success was achieved in 93% of group I, 88% of
Discussion
The ICRB was designed to simplify retinoblastoma classification and to predict treatment success with current methods, specifically CRD.12, 13, 16 This classification was not intended to predict life prognosis or visual outcome. It was intended to predict globe outcome, specifically, avoidance probability of enucleation and EBRT after CRD. In this study, we have shown that the ICRB is predictive of globe outcome after CRD. Patients within groups A, B, and C had a considerable chance for globe
References (17)
- et al.
Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation
Am J Ophthalmol
(2002) - et al.
Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors
Am J Ophthalmol
(2004) - et al.
Chemoreduction in the management of retinoblastoma
Am J Ophthalmol
(2005) - et al.
The evaluation and current concept of retinoblastoma therapy
Trans Am Acad Ophthalmol Otolaryngol
(1963) - et al.
Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma
Arch Ophthalmol
(1996) - et al.
Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy
Arch Ophthalmol
(1996) - et al.
Chemotherapy plus local treatment in the management of intraocular retinoblastoma
Arch Ophthalmol
(1996) - et al.
Chemoreduction in the initial management of intraocular retinoblastoma
Arch Ophthalmol
(1996)
Cited by (0)
Manuscript no. 2005-1095.
Supported by a donation from Michael, Bruce, and Ellen Ratner, New York, New York (JAS, CLS); the Paul Kayser International Award of Merit in Retina Research, Houston, Texas (JAS); the National Institutes of Health, Bethesda, Maryland (NIH R25 training grant [AKA]); Mellon Charitable Giving from the Martha W. Rogers Charitable Trust, Philadelphia, Pennsylvania (CLS); the Macula Foundation, New York, New York (CLS); and the Eye Tumor Research Foundation, Philadelphia, Pennsylvania (CLS, JAS).